EAM
GSK icon

Eagle Asset Management’s GSK GSK Stock Holding History

Eagle Asset Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$675K Buy
18,610
+1,888
+11% +$77.2K ﹤0.01% 497
2024
Q2 		$642K Buy
16,722
+255
+2% +$10.7K ﹤0.01% 522
2024
Q1 		$699K Buy
+16,467
New +$679K ﹤0.01% 520
2022
Q3 		– Sell
-14,664
Closed -$797K – 558
2022
Q2 		$797K Sell
14,664
-1,709
-10% -$94.3K 0.01% 499
2022
Q1 		$891K Buy
+16,373
New +$889K ﹤0.01% 514
2020
Q4 		– Sell
-95,939
Closed -$4.49M – 612
2020
Q3 		$4.49M Buy
95,939
+14,914
+18% +$747K 0.02% 372
2020
Q2 		$4.13M Buy
81,025
+9,438
+13% +$484K 0.02% 385
2020
Q1 		$3.39M Sell
71,587
-3,450
-5% -$184K 0.02% 401
2019
Q4 		$4.41M Buy
75,037
+2,571
+4% +$143K 0.02% 424
2019
Q3 		$3.87M Buy
72,466
+18,804
+35% +$967K 0.02% 446
2019
Q2 		$2.68M Buy
53,662
+6,772
+14% +$340K 0.01% 473
2019
Q1 		$2.45M Buy
46,890
+10,856
+30% +$542K 0.01% 488
2018
Q4 		$1.72M Buy
36,034
+7,712
+27% +$380K 0.01% 501
2018
Q3 		$1.38M Buy
28,322
+5,275
+23% +$268K 0.01% 543
2018
Q2 		$1.16M Buy
+23,047
New +$1.16M 0.01% 549
2017
Q4 		– Sell
-10,296
Closed -$526K – 637
2017
Q3 		$526K Buy
10,296
+1,366
+15% +$69.3K ﹤0.01% 574
2017
Q2 		$481K Buy
8,930
+876
+11% +$46.7K ﹤0.01% 587
2017
Q1 		$424K Buy
8,054
+1,234
+18% +$62.6K ﹤0.01% 604
2016
Q4 		$328K Buy
6,820
+1,089
+19% +$53.8K ﹤0.01% 601
2016
Q3 		$308K Buy
5,731
+844
+17% +$46.3K ﹤0.01% 602
2016
Q2 		$264K Buy
+4,887
New +$257K ﹤0.01% 611
2014
Q1 		– Sell
-911,672
Closed -$61.1M – 663
2013
Q4 		$61.1M Sell
911,672
-874,770
-49% -$56.7M 0.34% 93
2013
Q3 		$113M Buy
1,786,442
+930,856
+109% +$59.9M 0.56% 41
2013
Q2 		$53.4M Buy
+855,586
New +$54.3M 0.35% 79

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eagle Asset Management's GSK Position: Q3 2024 in Review

Eagle Asset Management increased its GSK (GSK) stake by 11% in Q3 2024, buying an estimated $77.2K and bringing the position to 18,610 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #497.

Eagle Asset Management first reported a position in GSK in Q2 2013 and has held it in 24 quarters since. The position peaked at $113M in Q3 2013. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

  • Eagle Asset Management held 18,610 shares of GSK worth $675K as of Q3 2024.
  • Eagle Asset Management bought 1,888 GSK shares in Q3 2024, an estimated $77.2K.
  • GSK made up ﹤0.01% of Eagle Asset Management's portfolio in Q3 2024, its #497 holding.
  • Eagle Asset Management first reported a position in GSK in Q2 2013 and has held it in 24 quarters since.
  • Eagle Asset Management's GSK position peaked at $113M in Q3 2013.
  • 899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.